Related Experiment Video
Updated: Jun 3, 2025
09:16
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
17.5K
Do SGLT2 Inhibitors Protect the Kidneys? An Alternative Explanation
1Sheba Medical Center, Institute of Endocrinology, Tel-Hashomer, Israel.
Endocrine, Metabolic & Immune Disorders Drug Targets
|January 10, 2025
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may not prevent kidney disease progression. Instead, they might alter lab results, creating a false impression of improved kidney function and clinical outcomes.
Area of Science:
- Nephrology
- Pharmacology
- Internal Medicine
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are used to treat diabetes mellitus.
- Randomized controlled trials suggest SGLT2 inhibitors may prevent kidney deterioration in diabetic and non-diabetic nephropathies.
Purpose of the Study:
- To propose a theory that SGLT2 inhibitors alter laboratory results rather than prevent renal disease progression.
- To explain the discrepancy between improved biochemical markers and inconsistent clinical outcomes in SGLT2 inhibitor studies.
Main Methods:
- Theoretical analysis of existing randomized controlled trial data.
- Examination of the effects of SGLT2 inhibitors on renal creatinine and microalbumin excretion kinetics.
Main Results:
- Biochemical markers like proteinuria and serum creatinine levels improve with SGLT2 inhibitors.
- Clinical outcomes such as mortality, need for dialysis, or renal transplant do not consistently improve.
Conclusions:
- SGLT2 inhibitors may change the kinetics of renal creatinine and microalbumin excretion, not halt kidney damage.
- This creates a dissociation between renal function markers and actual kidney function, impacting clinical prognosis.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
01:27Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
01:32Secondary Active Transport
6.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.8K
01:06Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
01:24Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295